KCT0003213已完成未知
A clinical trial to evaluate the pharmacokinetics ans safety of NVP-1402 compared with Exelon capsule in healthy male subjects
avipharm0 个研究点目标入组 38 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- Male
入选标准
- •1)Healthy adult male volunteers aged 19years old at screening
- •2)Body weight ? 50 kg within the range of ± 20% of the calculated ideal body weight (IBW)
- •? IBW(kg) = {height (cm) – 100} x 0.9
- •3)Without any congenital or chronic diseases requiring treatment, any pathological symptoms, or any abnormal findings on medical examination
- •4)Subjects evaluated eligible for the study based on the screening test results such as laboratory tests including serology, hematology, blood chemistry, and urinalysis, etc. and electrocardiogram(ECG).
- •5)Subjects who signed on the written informed consent form and comply with study requirements after listening and fully understanding the details of this study.
排除标准
- •1) Subjects with hypersensitivity to the active ingredients or other components of the investigational product(s) or medical history of significant hypersensitivity to other drugs or any additive(s).
- •2) Subjects with medical history to affect absorption, distribution, metabolism and elimination of drug(s) (disease(s) of hepatic/biliary, renal, cardiovascular, endocrine (hypothyroidism etc.), respiratory, digestive, hematologic, central nervous, psychiatric, musculoskeletal systems, etc.)
- •3) Subjects with active liver disease or alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels >1.5 times the upper limit of the normal range
- •4) Subjects with creatinine clearance <80 mL/min (Creatinine clearance calculated by Cockcroft-Gault’s formula using serum creatinine).
- •5) Subjects with gastrointestinal disease (Crohn's disease, active peptic ulcer disease, etc.) that would affect absorption of investigational products or history of gastrointestinal surgery (except for simple appendectomy or hernia surgery)
- •6) Subjects with serious harms, surgical procedures or suspected symptoms of acute disease(s) (severe infection, severe injury, etc.) within 4 weeks prior to the first administration.
- •7) Subjects who continued excessive drinking alcohol (>21 units/week, 1unit=10g=12.5 mL of pure alcohol) or could not abstain from alcohol since 3 days before the day to conduct the study or excessive smokers (> 10 cigarettes /day).
- •8) History of Substance abuse
- •9) Ingesting any prescription drug(s) or herbal medicine(s) within 2 weeks prior to the first administration or any over-the-counter (OTC) drug(s) judged by the investigator to affect this study or the safety of the study subjects.
- •10) Subjects who participated in any other study within 3 months prior to the first administration (the end of the previous study is determined as the last day of administration).
- •11) Subjects who donated whole blood or partial blood within 2 or 1 month, respectively, prior to the first administration.
- •12) Subjects on abnormal diets which might affect absorption, distribution, metabolism and elimination of drug(s) or taking foods which might affect drug metabolism.(eg, grapefruit juice (1L or more per day) taken within 7 days prior to administration of the Investigational Product)
- •13) Someone who can't take a meal derived from this trial
- •14) Subjects with positive result of serologic test (HBsAg, HCV Ab, HIV Ab)
- •15) Subjects judged not eligible for this study by principal investigator or subinvestigator (physician in charge).
研究者
相似试验
进行中（未招募）
不适用
The Pharmacokinetic Study of the Fixed-dose Combination of Micronized Fenofibrate and Pitavastatin CaDiseases of the circulatory systemKCT0001258Hanlim Pharmaceutical40
已完成
不适用
A clinical study to evaluate the pharmacokinetics of colistin and to explore biomarkers for nephrotoxicity in healthy volunteersKCT0005944Kyung Hee University Hospital12
招募中
不适用
Clinical trial to assess the pharmacokinetic characteristics of Lodivixx tab. 5/160mg in healthy male subjectsDiseases of the circulatory systemKCT0000710Hanlim Pharmaceutical60
招募中
不适用
Clinical trial to assess the pharmacokinetic characteristics of Lodivixx tab. 5/160mg in healthy male subjectsDiseases of the circulatory systemKCT0000489Hanlim Pharmaceutical40
进行中（未招募）
不适用
Clinical trial to assess the pharmacokinetic/Pharmacodynamic characteristics and safety/tolerability of CKD-519 new formulation in healthy male subjectsEndocrine, nutritional and metabolic diseaseKCT0001729Chong Kun Dang30